The Company announced the development of the first antiviral to combat BK virus, one of the most common viral infections in transplant patients CANTON, Mass.–(BUSINESS WIRE)–July 24, 2023– Orthogon ...
Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research funded by Kidney Research UK and York Against Cancer. The study, published in Science ...
Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...
Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research. The study, published in Science Advances by Dr. Simon Baker and colleagues at the ...
CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics LLC, a drug development company focused on designing innovative antivirals and anti-infective therapeutics, announced that it has raised an $8M ...
Erratum: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study The August 20, 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results